Study S002821

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

ClinicalTrials.gov record

Registration

Registration: NCT03072407
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: COMPLETED
Enrollment: 40
Start: 2015-11-24
Primary completion: 2016-11-02
Lead sponsor: PegBio Co., Ltd.
Conditions: Type2 Diabetes Mellitus
Interventions: BIOLOGICAL:PB-119 injection; BIOLOGICAL:PB-119 injection placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

the number of AEs and the finding from the physical examination, the abnormal lab results [accessed up to 4 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.